For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Avixgen Inc.

USPTO Granted Patents = 11

% Expired Patents = 18.2

EPO Patents = 4

Forward Citations = 6

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Yi Yong Baek (7 out of 7 patents)

Hye Cheong Koo (5 out of 5 patents)

Jun Sub Choi (4 out of 4 patents)

4. Young Myeong Kim (3 out of 3 patents)

5. Min Jung Kim (3 out of 61 patents)

6. Ji Chang You (3 out of 5 patents)

7. Won Jin Park (2 out of 4 patents)

8. Dong Hyun Jo (2 out of 7 patents)

9. Jeong Hun Kim (2 out of 48 patents)

10. Chul Ho Lee (1 out of 57 patents)

11. Jun-Sub Choi (1 out of 6 patents)

12. Dong Keon Lee (1 out of 1 patent)

13. Gyoon Hee Han (1 out of 11 patents)

14. Doo Na Song (1 out of 1 patent)

15. Koo Hwan Chung (1 out of 1 patent)

11 patents: Sort by Forward Citations

1. 11702449 - Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient (2023-07-18),

2. 11547649 - Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients (2023-01-10),

3. 11208433 - Peptide for inhibiting skin inflammation and composition for preventing or treating skin inflammation containing the same (2021-12-28),

4. 11141407 - Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative (2021-10-12),

5. 11040999 - Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient (2021-06-22),

6. 10821101 - Pharmaceutical composition for preventing or treating AIDS comprising rhodanine derivative (2020-11-03),

7. 10231971 - Pharmaceutical composition for preventing and treating dry eye diseases, containing imatinib as active ingredient (2019-03-19),

8. 10149888 - Method of inhibiting HIV replication utilizing the P7 nucleocapsid protein (2018-12-11),

9. 9969771 - Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof (2018-05-15),

10. 9738905 - Vector for expressing NC protein of HIV and method for producing NC protein using the same (2017-08-22),

11. 8759536 - Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients (2014-06-24),

Company Overview

Avixgen Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of innovative therapeutic solutions. The organization focuses on harnessing advanced technologies in the fields of gene therapy and regenerative medicine. Avixgen's research is aimed at addressing unmet medical needs through the creation of novel treatments that leverage its expertise in molecular biology and genetic engineering. The company is committed to advancing healthcare by translating scientific discoveries into practical applications.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

11 Patents

#371 in Seoul

#1,009 in South Korea

#51,714 in the World

Seoul, South Korea

Avixgen Inc.

Forward Citations = 6

18 inventors:

Yi Yong Baek (7 out of 7 patents)

Hye Cheong Koo (5 out of 5 patents)

Jun Sub Choi (4 out of 4 patents)

4. Young Myeong Kim (3 out of 3 patents)

5. Min Jung Kim (3 out of 61 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Avixgen Inc.. Retrieved from https://idiyas.com/company/avixgen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…